Cited by 758
Nisshinbo Holdings (Japan)
Publishes on Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Ionic liquids properties and applications. 34 papers and 1.1k citations.
Add your photo, update your bio, and get notified when your ranking changes.
© The Electrochemical Society, Inc. 2005. All rights reserved. Except as provided under U.S. copyright law, this work may not be reproducted, resold, distributed, or modified without the express permission of The Electrochemical Society (ECS). The archival version of this work was published in JOURNAL OF THE ELECTROCHEMICAL SOCIETY 152 (4): A710-A715 2005.
Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase activity. To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. However, the reverse situation has not been reported. Here, we present the first case with non-small cell lung cancer harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. As far as we know, this is the first report showing the efficacy of gefitinib for a non-small cell lung cancer patient who developed severe hepatotoxicity while under erlotinib therapy.
Transient AC optoelectronic conversion at the perovskite–ionic liquid interface associated with induced electric double layers is implemented for energy harvesting.